The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Abstract
The antitumor antibiotic, adriamycin, induces severe cardiac toxicity associated with peroxidation of cardiac lipids in mice. Both this lipid peroxidation and cardiac toxicity of adriamycin are reduced by prior treatment of the animals with the free radical scavenger tocopherol. Such treatment with tocopherol does not, however, alter the magnitude or duration of the adriamycin-induced suppression of DNA synthesis in P388 ascites tumor, nor does it diminish the antitumor responsiveness of P388 ascites tumor. These results suggest that adriamycin has at least two mechanisms of tissue damage: one, which involves lipid peroxidation, is blocked by tocopherol and results in cardiac toxicity; the other, which involves binding to DNA, is not antagonized by tocopherol and is responsible for tumor response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters
Dahle, L. K., Hill, E. G., & Holman, R. T. (1962) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(62)90181-9 · Cited by 839
Chemiluminescence and superoxide production by myeloperoxidase-deficient leukocytes.
Rosen, H., & Klebanoff, S. J. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108458 · Cited by 368
An enzymatic protective mechanism against lipid peroxidation damage to lungs of ozone‐exposed rats
Chow, C. K., & Tappel, A. L. (1972) · Lipids · doi:10.1007/bf02533017 · Cited by 344
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
Minow, R. A., Benjamin, R. S., & Gottlieb, J. A. (1975) · Cited by 274
Zimmermann, R., Flohé, L., Weser, U., & Hartmann, H.-J. (1973) · FEBS Letters · doi:10.1016/0014-5793(73)80539-3 · Cited by 158
Oxidative Hemolysis and Erythrocyte Metabolism in Hereditary Acatalasia*
Jacob, H. S., Ingbar, S. H., & Jandl, J. H. (1965) · Journal of Clinical Investigation · doi:10.1172/jci105225 · Cited by 149
Adriamycin: amelioration of toxicity by alpha-tocopherol.
Myers, C. E., McGuire, W. P., & Young, R. C. (1976) · PubMed · Cited by 104
Self-citation
Cited by
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Superoxide radical and superoxide dismutases
Fridovich, I. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000525 · Cited by 3,455
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Biomarkers of free radical damage
de Zwart, L. L., Meerman, J. H. N., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00196-8 · Cited by 838
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Self-citationŠimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Self-citationBatist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Minotti, G., & Aust, S. D. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75755-x · Cited by 544
Lipoprotein oxidation and lipoprotein-induced cytotoxicity.
Hessler, J. R., Morel, D. W., Lewis, L. J., & Chisolm, G. M. (1983) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.3.3.215 · Cited by 541
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.
Bachur, N. R., Gordon, S. L., Gee, M. V., & Kon, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.2.954 · Cited by 489
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Conklin, K. A. (2000) · Nutrition and Cancer · doi:10.1207/s15327914nc3701_1 · Cited by 464
Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., & St Clair, D. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118909 · Cited by 459
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Role of oxidative stress in transition of hypertrophy to heart failure
Dhalla, A. K., Hill, M. F., & Singal, P. K. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00140-4 · Cited by 427
Free radical formation by antitumor quinones
Powis, G. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90162-7 · Cited by 423
Electrochemical Reduction of Quinones in Different Media: A Review
Guin, P. S., Das, S., & Mandal, P. C. (2011) · International Journal of Electrochemistry · doi:10.4061/2011/816202 · Cited by 411
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
Rietjens, I. M. C. M., Boersma, M. G., Haan, L. D., Spenkelink, B., Awad, H. M., Cnubben, N. H. P., van Zanden, J. J., Woude, H. V. D., Alink, G. M., & Koeman, J. H. (2002) · Environmental Toxicology and Pharmacology · doi:10.1016/s1382-6689(02)00003-0 · Cited by 406
Initiation of lipid peroxidation in biological systems
Kanner, J., German, J. B., Kinsella, J. E., & Hultin, H. O. (1987) · C R C Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398709527457 · Cited by 382
Kotamraju, S., Konorev, E. A., Joseph, J., & Kalyanaraman, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003890200 · Cited by 372
Oxygen free radicals and human disease
Martínez-Cayuela, M. (1995) · Biochimie · doi:10.1016/0300-9084(96)88119-3 · Cited by 370
MARKS, L., YU, X., VUJASKOVIC, Z., SMALLJR, W., FOLZ, R., & ANSCHER, M. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00034-1 · Cited by 364
Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure.
Arai, M., Matsui, H., & Periasamy, M. (1994) · Circulation Research · doi:10.1161/01.res.74.4.555 · Cited by 359
Initiation of membranal lipid peroxidation by activated metmyoglobin and methemoglobin
Kanner, J., & Harel, S. (1985) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(85)90282-6 · Cited by 359
Song, Y., & Buettner, G. R. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.05.009 · Cited by 359
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Cappetta, D., De Angelis, A., Sapio, L., Prezioso, L., Illiano, M., Quaini, F., Rossi, F., Berrino, L., Naviglio, S., & Urbanek, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1521020 · Cited by 350
The role of oxidative stress in the genesis of heart disease
Singal, P. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00244-2 · Cited by 345
Shlafer, M., Kane, P. F., & Kirsh, M. M. (1982) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)37178-8 · Cited by 345
Lipid Peroxidation and Mechanisms of Toxicity
Horton, A. A., Fairhurst, S., & Bus, J. S. (1987) · CRC Critical Reviews in Toxicology · doi:10.3109/10408448709089856 · Cited by 339
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Park, J., Fong, P. M., Lu, J., Russell, K. S., Booth, C. J., Saltzman, W. M., & Fahmy, T. M. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.02.002 · Cited by 339
Free Radicals in Medicine. II. Involvement in Human Disease
SOUTHORN, P. A., & POWIS, G. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64862-9 · Cited by 339
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
Hatam, L. J., & Kayden, H. J. (1979) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40587-5 · Cited by 334
NAGI, M. N., & MANSOUR, M. A. (2000) · Pharmacological Research · doi:10.1006/phrs.1999.0585 · Cited by 331
Kalyanaraman, B. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101394 · Cited by 326
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Kalyanaraman, B., Perez-Reyes, E., & Mason, R. P. (1980) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(80)90142-7 · Cited by 317
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Unsal, V., Dalkiran, T., Çiçek, M., & Kölükçü, E. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.023 · Cited by 305
Kang, Y. J., Chen, Y., & Epstein, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12610 · Cited by 303
3-D Tumor Model for In Vitro Evaluation of Anticancer Drugs
Horning, J. L., Sahoo, S. K., Vijayaraghavalu, S., Dimitrijevic, S., Vasir, J. K., Jain, T. K., Panda, A. K., & Labhasetwar, V. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800047v · Cited by 292
Singh, K., Bhori, M., Kasu, Y. A., Bhat, G., & Marar, T. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.12.013 · Cited by 288
WANG, S., KOTAMRAJU, S., KONOREV, E., KALIVENDI, S., JOSEPH, J., & KALYANARAMAN, B. (2002) · Biochemical Journal · doi:10.1042/bj20020752 · Cited by 286
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995) · Circulation · doi:10.1161/01.cir.91.1.10 · Cited by 285
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, E., Ungvári, Z., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
Kunisada, K., Negoro, S., Tone, E., Funamoto, M., Osugi, T., Yamada, S., Okabe, M., Kishimoto, T., & Yamauchi-Takihara, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.315 · Cited by 273
Doxorubicin-dependent lipid peroxidation at low partial pressures of O2
Winterbourn, C. C., Gutteridge, J. M. C., & Halliwell, B. (1985) · Journal of Free Radicals in Biology & Medicine · doi:10.1016/0748-5514(85)90028-5 · Cited by 272
Metabolism and reactions of quinoid anticancer agents
Powis, G. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90105-7 · Cited by 270
Artesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells
Efferth, T., Giaisi, M., Merling, A., Krammer, P. H., & Li-Weber, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000693 · Cited by 256
Ito, H., Miller, S. C., Billingham, M. E., Akimoto, H., Torti, S. V., Wade, R., Gahlmann, R., Lyons, G., Kedes, L., & Torti, F. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4275 · Cited by 255
Kang, Y. J., Chen, Y., Yu, A., Voss-McCowan, M., & Epstein, P. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119672 · Cited by 253
Negoro, S., Kunisada, K., Fujio, Y., Funamoto, M., Darville, M. I., Eizirik, D. L., Osugi, T., Izumi, M., Oshima, Y., Nakaoka, Y., et al. (2001) · Circulation · doi:10.1161/hc3401.095947 · Cited by 252
Sturgill, M. G., & Lambert, G. H. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.8.1512 · Cited by 252
Protective effect ofSpirulina against doxorubicin-induced cardiotoxicity
Khan, M., Shobha, J. C., Mohan, I. K., Naidu, M. U. R., Sundaram, C., Singh, S., Kuppusamy, P., & Kutala, V. K. (2005) · Phytotherapy Research · doi:10.1002/ptr.1783 · Cited by 159
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Berthiaume, J. M., Oliveira, P. J., Fariss, M. W., & Wallace, K. B. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:257 · Cited by 101
Sugiyama, T., & Sadzuka, Y. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.040 · Cited by 95
DeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Harris, B., Hadley, R., Cole Harper, P., Carney, J. M., & Butterfield, D. A. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00306-1 · Cited by 89
The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin
Sadzuka, Y., Sugiyama, T., Miyagishima, A., Nozawa, Y., & Hirota, S. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04282-6 · Cited by 68
Capizzi, R. L. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00333-4 · Cited by 66
(1999) · PubMed · Cited by 45
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Effects of Water-Soluble Antioxidant from Spinach, NAO, on Doxorubicin-Induced Heart Injury
Breitbart, E., Lomnitski, L., Nyska, A., Malik, Z., Bergman, M., Sofer, Y., Haseman, J. K., & Grossman, S. (2001) · Human & Experimental Toxicology · doi:10.1191/096032701680350604 · Cited by 31
Metadata
- Authors
- Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C.
- Venue
- Science
- Published
- 1977-07-08
- Volume
- 197
- Issue
- 4299
- Pages
- 165-167
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992786087
- Cited by
- 1,111
- References
- 8
- FWCI
- 27.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.